Merck Receives Another Boost for Its Top-Selling Drug
With pharma stock AbbVie (NYSE: ABBV) set to lose U.S. exclusivity for its immunology drug Humira in 2023, analysts believe that Merck's (NYSE: MRK) cancer drug Keytruda will soon claim Humira's crown as the top-selling medicine in the world. Keytruda recently advanced down that road with a major regulatory approval. In late October, the European Commission (EC) approved it in combination with chemotherapy to treat patients with locally recurrent, unresectable or metastatic triple-negative breast cancer (TNBC) in the European Union (E.U.).
